- 1 Single-cell RNA sequencing reveals a novel cell type and immunotherapeutic
- 2 targets in papillary thyroid cancer
- 3 Zhengshi Wang^{1,2,†}, Youlutuziayi Rixiati^{3,†}, Wenli Jiang^{4,†}, Chen Ye⁵, Caiguo Huang⁴,
- 4 Chuangang Tang^{6,*}, Zhiqiang Yin^{1,2,*}, Binghua Jiao^{4,*}
- 6 ¹ Thyroid Center, Shanghai Tenth People's Hospital, Tongji University School of
- 7 Medicine, Shanghai, P.R.China;
- 8 ² Shanghai Center for Thyroid Diseases, Shanghai, 200072, P.R.China;
- 9 ³ Department of Pathology, Soochow University Medical School, Suzhou, 215123,
- 10 P.R.China:

- ⁴ Department of Biochemistry and Molecular Biology, College of Basic Medical,
- 12 Navy Medical University, Shanghai, 200433, P.R.China;
- ⁵ Department of Urology, Changhai Hospital, Navy Medical University, Shanghai,
- 14 200433, P.R.China;
- ⁶ Department of Thyroid and Breast Surgery, Xuzhou Central Hospital, The Affiliated
- 16 Xuzhou Hospital of Medical College of Southeast University, Xuzhou, 221009,
- 17 P.R.China.

- [†]They contributed equally to the manuscript.
- 20 *Corresponding authors:
- 21 Binghua Jiao, PhD. Department of Biochemistry and Molecular Biology, College of
- 22 Basic Medical, Navy Medical University, Shanghai, 200433, P.R.China. Tel:
- 23 +86-13801924888, Email: <u>biojiao@163.com</u>.
- 24 Zhiqiang Yin, MD. Shanghai Center for Thyroid Diseases, No. 301, Middle
- 25 Yanchang Road, Shanghai, P.R.China. Tel.: +86-18917689323, Email:
- 26 972683004@qq.com
- 27 Chuangang Tang, MD. Department of Thyroid and Breast Surgery, Xuzhou Central
- 28 Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University,
- 29 Xuzhou, 221009, P.R.China. Tel.: +86-18652230137, Email: tcg3711@163.com.

Abstract

30

31 Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Although 32 PTC usually has a favorable prognosis, some aggressive PTC subtypes and lymph 33 node (LN) metastasis contribute to high rates of recurrence and poor clinical 34 outcomes. We analyzed single-cell RNA sequencing (scRNA-seq) data from 15 35 samples, including primary tumors of PTC, metastatic LNs, and paracancerous tissues. 36 After quality filtering, 28,205 cells were detected. Of these, 13,390 cells originated 37 from 7 tumor tissues, 2,869 cells from 2 metastatic LNs, and 11,945 cells from 6 38 paracancerous tissues. The increase in the proportion of CD4⁺ Tregs may be a key 39 factor responsible for the immunosuppressive property of PTC. A novel cell type was identified, named Protective EGR1⁺CD4⁺ T cell, which might be antagonistic to the 40 41 CD4⁺ Tregs and inhibit the formation of the immunosuppressive microenvironment 42 and tumor immune evasion. Inhibitory checkpoints TIGIT and CD96 were found to be 43 better targets than PD-1 for immune therapy in PTC patients with LN metastasis. For 44 PTC patients without LN metastasis, however, PD-1, TIGIT, and CD96 could be 45 suitable targets of immunotherapy. These findings would contribute to the further 46 understanding of molecular mechanisms resulting in occurrence and development of 47 PTC, and provide a theoretical rationale for targeted therapy and immunotherapy. 48

Keywords

50 51

49 papillary thyroid cancer, single-cell RNA sequencing, tumor microenvironment

Introduction

According to the GLOBOCAN database, there were an estimated 586,202 new cases of thyroid cancer worldwide in 2020 ¹. The global incidence was up to 13.1 per 100,000 people, ranking 11th in occurrence rate. The most common pathological type of thyroid cancer is papillary thyroid cancer (PTC), accounting for approximately 85% of all cases ². Although PTC usually has a favorable prognosis, some aggressive PTC subtypes (e.g. tall cell variant and Hürthle cell cancer) and lymph node (LN) metastasis contribute to high rates of recurrence and poor clinical outcomes ^{3, 4}. For PTC patients with a high risk of recurrence, radioiodine treatment could be used to improve their prognosis ⁵. However, some PTC patients would develop into radioiodine-refractory PTC, which in turn lead to low survival rate ^{6, 7}. Therefore, a deeper understanding of molecular and cellular mechanisms of PTC would help in the development of therapeutic strategies.

Currently, efforts to study the tumor progression and metastatic process of thyroid cancer have mainly focused on the analysis of cancer cells using genetic aberrations^{8, 9, 10, 11}. However, the tumor progression and metastasis are a complicated biological process, which were not only affected by the characteristic features of cancer cells themselves but also by the tumor microenvironment (TME) ^{12, 13, 14, 15}. TME refers to a tumor pathology-related environment, comprising stromal cells, extracellular matrix (ECM), and cytokines. A comprehensive analysis of TME in PTC can reveal the key elements involved in the susceptibility of tumor-induced immunological changes, which could be employed to develop new immunotherapy strategies.

Genomic and transcriptomic studies have revealed a huge number of driver mutations, abnormal regulatory programs, and disease subtypes in major human tumors ^{16, 17, 18, 19}. However, the conventional bulk sequencing frequently adopted in these studies only revealed the overall biological characteristics of each tumor and lacked the ability to capture signatures in intratumoral and intercellular heterogeneity. As opposed to bulk sequencing, the emergence of single-cell RNA sequencing (scRNA-seq) provided a new opportunity to enables characterization of cell populations at the single-cell level, and made it more independent of any previous assumptions about surface markers ²⁰. scRNA-seq has been applied to investigate cellular properties in various solid tumor types ²¹. However, the single-cell atlas of

- 85 PTC remains to be fully revealed. Therefore, we analyzed primary PTC tumors,
- 86 paracancerous tissues, and metastatic LNs using the scRNA-seq-based profiling
- 87 method to better understand the intratumoral heterogeneity and complexity during the
- 88 development of PTC.
 - Results

- Single cell atlas and heterogeneity of PTC
- 91 A total of 15 samples from seven PTC patients were involved in this study. After
- 92 quality filtering, 28,205 cells were detected. Of these, 13,390 cells originated from 7
- 93 tumor tissues, 2,869 cells from 2 metastatic LNs, and 11,945 cells from 6
- paracancerous tissues (Fig. 1a and 1b). Subsequently, we partitioned the cells into 26
- 95 clusters, which were further classified into 10 major cell types based on known
- markers described in previous studies: B cells (CD19⁺, MS4A1⁺, CD38⁺, CD79A⁺,
- 97 CD79B⁺); CD4⁺T cells (CD3D⁺, CD4⁺); CD8⁺T cells (CD3D⁺, CD8A⁺); endothelial
- 98 cells (CD31⁺, CD34⁺); epithelial cells (EPCAM⁺, KRT18⁺); fibroblasts (COL1A1⁺);
- 99 myeloid cells (CD14⁺, CD86⁺, ITGAX⁺, CD80⁺, CD83⁺, ITGAM⁺); naive T cells
- 100 (CD3D⁺, CCR7⁺); natural killer T (NKT) cells (CD3D⁺, NKG7⁺); and plasma cells
- 101 (CD79A⁺, SDC1⁺) (Fig. 1c, Supplementary Fig. 1 and 2).
- Based on the frequencies of cell types, we detected cellular landscapes in
- 103 primary tumors, paracancerous tissues, and metastatic LNs, respectively, significant
- differences were observed in several cell types (Fig. 1d). The immune cells accounted
- for the major differences between primary tumors and paracancerous tissues, with the
- frequency of NKT cells and plasma cells increasing, and CD4⁺ T cells and B cells
- decreasing in the primary tumors (P<0.05). The most striking changes between
- metastatic LNs and primary tumors were observed in CD8⁺ T cells. At the cluster
- 109 level, there were also significant differences within the same cell types. As
- exemplified by myeloid cells, we observed an increase in the frequency of cluster 21
- and a decrease in the proportion of cluster 25 in metastatic LNs compared with
- 112 primary tumors and paracancerous tissues. These results demonstrated that the disease
- 113 progression might also be somehow associated with evolutionary immune cells,
- reflecting the existence of heterogeneity among samples and cell populations.
- To conduct the interaction network of tumor microenvironment in PTC,
- 116 CellphoneDB was used to calculate potential ligand-receptor pairs in cells. And
- 117 Cytoscape was performed to visualize the cell interaction. We found that myeloid
- 118 cells and T cell-related cells possessed more interaction pairs with other cells than

others (Fig. 1e), showing the dominant roles of myeloid cells and T cells.

Identification of malignant cells in epithelial cells

- 121 To distinguish malignant from non-malignant cells within the epithelial cells,
- 122 CopyKAT was performed to identify PTC genome alterations. Despite the
- heterogeneity, almost all malignant cells possessed deletions from chromosomes 16
- and 19 and amplifications in chromosomes 13 (Fig. 2a and 2b). We distinguished
- 125 1,679 non-malignant cells and 450 cells were identified as malignant cells. Very few
- malignant cells were also found in paracancerous tissues (Fig. 2b). In order to support
- the identification results of the malignant cells, pseudotime trajectory analysis was
- performed. The results showed that malignant cells were present at the end of the
- differentiation trajectory (Fig. 2c).

120

- To screen for key regulons in malignant cells, we conducted SCENIC analysis
- and identified motifs ATF3 and BHLHE40 that were highly activated in malignant
- 132 cells (Fig. 2d). In a previous study, ATF3 was found to enhance breast cancer
- metastasis ³⁶. At the same time, decreased activity was found in CREM and ETS1. In
- 134 TCGA THCA cohort, a high level of CREM and ETS1 was significantly related to a
- good prognosis, and BHLHE40 is highly expressed in patients with LN metastasis
- compared with patients without LN metastasis (Fig. 2e and 2f). These results provide
- potential targets for suppressing cells to possess malignant characteristics.
- We further characterized the functions of differential genes between metastatic
- 139 LNs and primary tumors by comparing pathway activities. Pathways involved in
- 140 cellular component assembly, protein-containing complex assembly, and regulation of
- microtubule motor activity were relatively upregulated in LN-derived malignant cells
- 142 (Fig. 2g). The results showed that malignant cells in metastatic LNs have stronger cell
- proliferative and invasive abilities.

144

Identification of a novel T cell type

- Reclustering of T cells identified 10 subclusters: CD4⁺ Tregs, Cytotoxic CD8⁺T
- cells, Exhausted CD4⁺ T cells, Follicular helper (Tfh) T cels, Naïve CD4⁺ T cells,
- Naïve T cells; NKT cells, Pre-exhausted CD8⁺ T cells, Proliferating CD8⁺ T cells, and
- Protective EGR1⁺CD4⁺ T cells (Fig. 3a and 3b). In addition to the markers used above,
- we also found some other makers that can be used for cell population identification.
- For example, TYMS can be used for Pre-exhausted CD8⁺ T cells identification, and
- 151 RTKN2 can be used for Pre-exhausted CD4⁺ Tregs identification (Fig. 3c,
- Supplementary Fig. 3). Notably, a novel cell type was identified, which was totally

154

155

156

157

158

159

160 161

162

163

164

165

166

167

168

169

170171

172173

174 175

176

177

178

179

180

181

182

183

184 185

186

different from preconceived cellular definitions. The novel cell type specifically highly expressed EGR1, and we named it as Protective EGR1+CD4+T cells. The mRNA expression level and protein level of EGR1 were significantly decreased in tumor tissues compared with normal tissues (Fig. 3d). Survival analysis showed that patients with high EGR1 levels had a better prognosis than those with low EGR1 (Fig. 3e). Through cell frequency analysis, we found an interesting phenomenon that the proportion of CD4⁺ Tregs tended to increase with PTC disease progression and Protective EGR1 *CD4 * T cells exhibited a quite opposite trend (Fig. 3f). The results were validated with TCGA data calculated using Cibersortx (Fig. 3g) and further validated by the changes of marker gene expression levels in the TCGA THCA cohort (Supplementary Fig. 4a). These findings indicated that both of CD4⁺ Tregs and Protective EGR1⁺CD4⁺ T cells may have an important impact on disease progression, and our newly identified cell type (Protective EGR1 CD4 T cells) may be antagonistic to the CD4⁺ Tregs. We further characterized the functions of CD4⁺ Tregs and Protective EGR1⁺CD4⁺ T cells by comparing pathway activities. In the primary tumors, CD4⁺ Tregs and Protective EGR1⁺CD4⁺ T cells exhibited vastly different signaling pathways. CD4⁺ Tregs were related to epithelial-mesenchymal transition (EMT) and hypoxia, whereas G2M checkpoint and KRAS signaling pathway were significantly down-regulated in Protective EGR1⁺CD4⁺ T cells (Fig. 4a). In the metastatic LNs, mitotic spindle and oxidative phosphorylation were also down-regulated in Protective EGR1⁺CD4⁺ T cells (Supplementary Fig. 4b). To screen for key genes related to tumorigenesis and tumor development in CD4⁺ Tregs and Protective EGR1⁺CD4⁺ T cells, we conducted SCENIC analysis and identified essential motifs in CD4⁺ Tregs and Protective EGR1⁺CD4⁺ T cells. FOSL2, ATF3, REL, and HES1 were CD4⁺ Tregs-specific motifs. BCLAF1 and ETS1 motifs were highly activated in Protective EGR1⁺CD4⁺ T cells (Fig. 4b). These results provided potential targets for inhibiting or reversing the formation of the immunosuppressive microenvironment. The DEGs derived from Protective EGR1⁺CD4⁺ T cells were identified, including 31 up-regulated mRNAs and 50 down-regulated mRNAs in primary tumors compared with paracancerous tissues (Supplementary Fig. 4c). The DEGs derived from CD4⁺ Tregs were also identified (Supplementary Fig. 4d). Subsequently, we examined the immune checkpoints in the cell clusters (Fig. 4c and 4d). Notably, we found that TIGIT, an inhibitory checkpoint, was upregulated in Exhausted CD4⁺ T

187 cells and CD96 was upregulated in Pre-exhausted CD8⁺ T cells in metastatic LNs. In 188 tumor tissues, PDCD1 (PD-1) and TIGHT were significantly upregulated in 189 Exhausted CD4⁺ T cells, and CD96 was significantly upregulated in Pre-exhausted 190 CD8⁺ T cells. Since TIGIT, CD96, and PDCD1 (PD-1) are markers of T cell 191 exhaustion, these data indicated that Exhausted CD4⁺ T cells and Pre-exhausted CD8⁺ 192 T cells were exhausted in the tumor microenvironment, which was consistent with our 193 previous cell population classification results. 194 **Neutrophils cells are extremely reduced in tumor** 195 For exploring the heterogeneity among myeloid cells, 1607 myeloid cells were 196 clustered into 5 cell subtypes based on known markers described in previous studies: 197 macrophages, dendritic cells, monocytes, neutrophils, and myeloid-derived suppressor 198 cells (Fig. 5a and 5b). Through cell frequency analysis, a marked decrease of 199 neutrophils was observed in tumors while the proportion of macrophages increased 200 continuously as the disease progressed (Fig. 5c). The trend was consistent with TCGA 201 data calculated by cibersortx (Fig. 5d). Survival analysis showed that disease-free 202 survival (DFS) of patients with low-level dendritic cell was longer than that of the 203 high-level group in the TCGA cohort (Fig. 5e). Similar results were observed in 204 macrophages (Supplementary Fig. 5a). However, low-level neutrophil was observed 205 to be associated with better prognosis (Supplementary Fig. 5b). These results 206 suggested that macrophages, dendritic cells, and neutrophils are more relevant to the 207 development of PTC. 208 We further characterized the functions of myeloid cell subtypes by comparing 209 pathway activities. Compared with paracancerous tissues, the cancer hallmark-related 210 pathways were relatively enriched in myeloid-derived suppressor cells from tumors, 211 whereas they were generally down-regulated in neutrophils from tumors (Fig. 6a). 212 These were consistent with the changes in cell proportions we observed earlier (Fig. 213 5c). Compared with tumor tissues, however, some cancer hallmark-related pathways 214 (i.e. mTORC1 signaling and E2F targets) were down-regulated in myeloid-derived 215 suppressor cells from metastatic LNs (Fig. 6b). The results indicated that 216 myeloid-derived suppressor cells were involved in cancer cell proliferation, but not in 217 tumor metastasis. 218 In order to screen for key genes related to tumor occurrence and development in 219 myeloid cells, we conducted SCENIC analysis and identified essential motifs in

myeloid cells subtypes. Similar to the results of pathway analysis, the overall

regulatory factors in neutrophils were also inconsistent with the other cell types (Fig. 6c). We recognized that the decreased activity of a lot of motifs (i.e. YY1 and IRF5) and activation of the STAT3, ZNF143, and HCFC1 motifs led to the reduction of neutrophils.

As shown in Fig. 6d, cells from myeloid cell-derived cluster 8 uniquely expressed the M1 macrophages marker CCL5, whereas M2 macrophages markers including CTSB/CTSD/FN1 were relatively highly expressed in cluster 0. The proportion of cluster 0 was high in tumors and LNs, although the difference has not reached a significant level (Fig. 5c). All of this evidence certified that cluster 0 represented an M2-like tumor-associated macrophages (TAM) cluster, the increase of which may be related to disease progression. Cluster 9 highly expressed the cytokines CCL17/CCL19/CCL22. These cytokines could bind to CCR4, a marker on the cell membrane of CD4⁺ Tregs, and showed strong chemotaxis to CD4⁺ Tregs with disease progression was coincident with that of myeloid cell-derived cluster 9 (Fig. 3f and 5c). The findings indicated that the dendritic cells (cluster 9) could recruit CD4⁺ Tregs into the tumor regions, thereby acting as an immunosuppressive effect.

Discussion

At present, the study of molecular mechanisms underlying the occurrence and development of PTC mainly focused on the genetical alteration based on bulk sequencing data. We profiled integrated and heterologous transcriptional landscapes of PTC using single-cell sequencing methods, including cancer cells and TME of primary tumors and metastatic lesions. Through sequencing 28,205 cells, we found that the majority of cell clusters possessed strong heterogeneities. Tumor heterogeneity exists in various malignancies and remains not only between tumors but also within a single tumor ³⁹, which is considered as a cause of chemoresistance of cancer. In-depth knowledge of tumor heterogeneity of PTC will make molecular testing more reliable and accurate prior to surgery (whether to undergo the surgery or close follow-up only), and benefit to stratify the recurrence risk and personalized precision treatment (thyroidectomy or total thyroidectomy or plus radioiodine treatment). On the other hand, TME on disease progression and metastasis has also been confirmed in numerous diseases 40,41. Investigations of TME-related cellular and molecular events will provide a theoretical rationale for drug discovery and development, especially for targeted therapy and immunotherapy.

256

257

258 259

260

261262

263

264

265

266

267

268

269

270

271272

273274

275

276

277

278

279

280

281 282

283

284 285

286

287

288

In addition to previously described cell types, we discovered a novel cell subpopulation, named Protective EGR1 CD4 T cells. EGR1 is a transcription factor primarily mediate cellular functions (i.e. cell growth, cancer progress and apoptosis) via the RAS/RAF/MEK/ERK signaling pathway ⁴², which was a hallmark of PTC ⁴³. It has also been previously reported that p53 could bind to EGR1 promoter and subsequently resulted in efficient apoptosis ⁴⁴. EGR1 was usually considered a tumor suppressor in many human malignancies including PTC 45, 46, 47, 48. By comparing the proportion of cells from different tissues and pathway enrichment analyzing, we found that KRAS signaling pathway (part of RAS/RAF/MEK/ERK signaling pathway) was significantly down-regulated in Protective EGR1 CD4 T cells. It indicated that Protective EGR1⁺CD4⁺T cells might inhibit the formation of the immunosuppressive microenvironment and tumor immune evasion via RAS/RAF/MEK/ERK signaling pathway, thereby restraining tumor growth. Therefore, EGR1 might represent a potential therapeutic target for PTC. CD4⁺ Tregs, were overall considered to disrupt anti-tumor immunity and then help tumor cells to achieve immune evasion, leading to the tumor growth and metastasis ⁴⁹. Our results also showed that CD4⁺ Tregs had the greatest positive correlation with the process of EMT, which matched those reported in other studies of PTC patients ⁵⁰. Using pathway enrichment analysis, we found that relevant pathways associated with CD4+ Tregs and Protective EGR1+CD4+T cells were almost the opposite. The proportion of CD4⁺ Tregs among three samples increased in the disease progression order (paracancerous tissues < tumors < LNs) while the proportion of Protective EGR1⁺CD4⁺T cells decreased sequentially. This strongly suggested that CD4⁺ Tregs and Protective EGR1⁺CD4⁺T cells might act antagonistically to each other. Immunotherapy is an emerging method for cancer treatment and promising results have been obtained in both hematologic and solid tumors ^{51, 52}. T cell exhaustion is a critical mechanism of immune evasion. Blockade the PD1/PDL1 interaction to reverse T cell exhaustion is considered a milestone achievement in the field of immunotherapy ^{53, 54, 55}. Our results showed that PDCD1 (PD-1), TIGIT, and CD96 could be suitable targets of immunotherapy in PTC patients without LN metastasis since they were upregulated in tumor tissues. However, the expression levels of TIGIT and CD96 were much higher than that of PDCD1 (PD-1) in LN-derived exhausted T cell types (Exhausted CD4⁺ T cells and Pre-exhausted CD8⁺

290 291

292

293

294

295

296

297

298 299

300

301

302

303

304

305

306

307 308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

T cells). Therefore, TIGIT and CD96 might be better therapeutic targets for immunotherapy in PTC patients with LN metastasis than PDCD1 (PD-1). Jill et al. ⁵⁶ investigated the CD4⁺ and CD8⁺ T cell exhaustion in PTC patients with LN metastasis using flow cytometry, and found that CD8+ T cell exhaustion was incomplete. This was most likely because TIGHT and CD96 were not included into analysis in their study, both of which were very important inhibitory immune checkpoints. However, their findings supported our conclusions to some extent that PDCD1 (PD-1) was not a suitable molecular target for the treatment of PTC with LN metastasis.

We initially applied a commonly used method inferCNV for the identification of malignant cells ⁵⁷, which was shown to be unable to identify efficiently malignant tumor cells from epithelial cells in this study. Thus, we adapted an integrative Bayesian segmentation approach called CopyKAT and solved the conundrum successfully ³⁵. As a result, more than half of tumor-derived epithelial cells were non-malignant cells, which might well explain the reason for the indolent clinical behavior of PTC. Additionally, there were also a very small number of malignant epithelial cells in paracancerous tissues, possibly due to the presence of the pre-tumor microenvironment in paracancerous tissues. There were several possible reasons. First, the pre-metastatic niche, a favorable microenvironment to tumor metastasis, formed in paracancerous tissues ⁵⁸, and in turn lead to intra-thyroid metastasis. The concept of intra-thyroid metastasis of thyroid cancer has not been described yet. The reason is possibly caused by the small size of the thyroid gland itself and the narrow lumen of artery/vein nourishing the thyroid gland. As is well-known, liver cancer tends to present with intrahepatic metastatic disease, mainly due to the large diameter of the portal vein and hepatic artery. Second, multifocal PTC has already existed within the thyroid gland, whereas the extremely tiny lesion cannot be detected under microscopic examination. Based on the two points above, thyroidectomy is necessary to be performed for patients with PTC at least to ensure a total removal of potential lesions. Third, CopyKAT is not able to discriminate malignant cells from non-malignant cells with hundred percent accuracy.

In summary, we initially investigated the single-cell level heterogeneity of primary PTC tumors and metastatic lesions. A novel cell type, named Protective EGR1+CD4+T cells, was identified, which might inhibit the formation of the immunosuppressive microenvironment and tumor immune evasion. TIGIT and CD96 might be better therapeutic targets for immunotherapy in PTC patients with LN

metastasis than PDCD1 (PD-1). These findings would contribute to the further understanding of molecular mechanisms resulting in occurrence and development of PTC, and provide a theoretical rationale for targeted therapy and immunotherapy.

Methods

327

328

334

356

Sample collection and clinical information

- 329 Seven patients diagnosed with PTC were obtained from Shanghai Tenth People's
- Hospital. A total of 15 tissue samples (7 tumor tissues, 6 paracancerous tissues, and 2
- metastatic LNs) were obtained from 7 PTC patients. Written informed consent was
- 332 obtained from all patients in the present study. Histological diagnosis of all the
- samples was confirmed by the pathology department.

Tissue digestion and single-cell suspension preparation

- 335 Cells of each sample were firstly stained with two fluorescent dye, Calcein AM
- 336 (Thermo Fisher Scientific Cat. No. C1430) and Draq7 (Cat. No. 564904), for
- 337 precisely determination of cell concentration and viability via BD RhapsodyTM
- 338 Scanner before single-cell multiplexing labeling. The cells of each sample were
- sequentially labeled with BD Human Single-Cell Multiplexing Kit (Cat. No. 633781)
- 340 which utilizing an innovative antibody-oligo technology ²² mainly to provide higher
- 341 sample throughput and eliminate batch effect for single-cell library preparation and
- sequencing. A set of 12 antibodies in this kit recognize the same universally expressed
- 343 cell-surface antigen of human cells. Each antibody is conjugated with a Sample Tag, a
- 344 unique 45-nucleotide barcode sequence. Briefly, cells from each sample were labeled
- 345 by antibodies with different sample tags respectively and washed twice with BD
- PharmingenTM Stain Buffer (FBS) (Cat. No. 554656) before pooling all samples
- 347 together. BD Rhapsody Express system²³based on Fan et al. was utilized for
- 348 single-cell transcriptome capturation. Pooled samples were then loaded in one BD
- 349 RhapsodyTM Cartridge that was primed and treated strictly following the
- 350 manufacturer's protocol (BD Biosciences). Cell Capture Beads (BD Biosciences)
- were then loaded excessively onto the cartridge to ensure that nearly every micro-well
- 352 contains one bead, and excess beads were washed away from the cartridge. Viable
- 353 cells with beads captured in wells were detected in BD RhapsodyTM. Then cells were
- 354 lysed, Cell Capture Beads were retrieved and washed before performing reverse
- 355 transcription and treatment with exonuclease I.

Library construction and sequencing

- 357 Transcriptome and SampleTag information of single-cells was obtained through BD
- 358 Rhapsody System. Microbeads-captured single cell transcriptome and SampleTag
- 359 sequences were generated into the cDNA library and SampleTag library separately

360 containing cell labels and unique molecular identifiers (UMI) information. Briefly, double-strand cDNA was firstly generated from microbeads-captured single-cell 362 transcriptome through several steps including reverse transcription, second-strand 363 synthesis, end preparation, adapter ligation, and whole transcriptome amplification. 364 Then final cDNA library was generated from double-strand full-length cDNA by 365 random priming amplification with BD Rhapsody cDNA Kit (BD Biosciences, 366 Catalog No.: 633773) and BD Rhapsody Targeted mRNA & AbSeq Amplification Kit 367 (BD Biosciences, Catalog No.: 633774). On the other hand, the SampleTag library 368 was generated from microbeads-captured single-cell SampleTag sequences through 369 several steps including reverse transcription, nest PCR, and final index PCR. Libraries 370 were sequenced on the NovaSeq platform (Illumina).

Raw data preprocessing and quality control

361

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393


Raw sequencing reads of the cDNA library and SampleTag library were processed through the BD Rhapsody Whole Transcriptome Assay Analysis Pipeline (Early access), which included filtering by reads quality, annotating reads, annotating molecules, determining putative cells, and generating single-cell expression matrix. Briefly, read pairs with low sequencing quality were firstly removed. The quality-filtered R1 reads were analyzed to identify the sequence of cell labels, UMI sequence, and poly-dT tail sequence, meanwhile the quality-filtered R2 reads were mapped to Genome Reference Consortium Human Build 38 (GRCh38) using STAR (version 2.5.2b) in the reads annotation step. Further adjustment was performed with the recursive substitution error correction (RSEC) and distribution-based error correction (DBEC) algorithms to remove artifact molecules due to amplification bias in the molecules annotation step. Putative cells were distinguished from background noise with second derivative analysis in the putative cell determination step. Finally, putative cells information was combined with molecules adjusted by the recursive substitution error correction and distribution-based error correction algorithms to generate a single-cell expression matrix. The pipeline also determined the sample origin of every single cells via the sample determination algorithm according to the sequencing reads of the SampleTag library. The algorithm classified all putative single cell into three categories: Multiplet, two or more SampleTag exceed their minimum thresholds, indicating more than one actual cell in one micro-well. Undetermined, not enough SampleTag reads for the sample origin. SampleTag01-12, only one SampleTag exceed their minimum thresholds. . Among all the output files, Matrix for

394 UMI counts per cell corrected by DBEC and SampleTag annotation result were used 395 for downstream clustering analysis. 396 **Dimension reduction and clustering** The R package Seurat ²³ was utilized for subsequent analysis. Raw gene expression 397 398 matrices from the cartridge were read into R (version 3.6.0) and converted to Seurat 399 objects. Cells label as "Undetermined" and "Multiple" were excluded in the following 400 analysis. The gene expression matrix was then normalized to the total cellular UMI 401 count. Top 2000 features were selected as highly variable genes for further clustering 402 analysis. In order to reduce dimensionality, PCA was performed based on the highly 403 variable genes after scaling the data with respect to UMI counts. On top of that, the 404 first 9 principal components were chosen for downstream clustering based on the 405 heatmap of principle components, and the elbow plot of principle components to 406 further reduce dimensionality using the UMAP algorithm. The transcriptional markers 407 of each cluster were calculated using the FindAllMarkers function with theMAST 408 package to run the DE testing under the following criteria: log2 fold change > 0.1; p < 409 0.05; min. percentage > 0.25. Top 500 markers of each cluster were then selected to 410 perform a heatmap plot. 411 Cell annotation and cell type identification 412 Cell populations were matched to cell types based on the expression of known marker genes and previously identified expression signatures ^{23, 24, 25, 26, 27, 28}. 413 414 Comparison of cell clusters and cell type proportion 415 The change in the fraction of the different cell types was separately computed for each 416 sample across all clusters, as the fraction of cell in each cluster, out of the total 417 number of cells ²⁹. To assess a statistically significant difference in a fraction of a 418 specific cell type, we performed paired t-test. 419 Significantly dysregulated genes identification We identified differentially expressed genes (DEGs) based on analysis of the MAST 420 421 package using the R. The threshold of DEGs was set as: 1)P-value of F test < 0.05; 2) 422 $|FC| \ge 1.5$. 423 **External data validation with TCGA datasets** 424 CIBERSORTx was used to detect the abundance of cell types identified in the present work in bulk RNA-seq data ³⁰. After calculated the relative abundance of each cell 425 426 type, we divided the patients into two groups: high 50% and low 50%. Subsequently,

Kaplan-Meier analysis was performed using ggsurvplot function of the R package

- 428 'survminer'. Whether the occurrence of cell types in the different subgroups showed
- 429 significant differences was evaluated by Wilcoxon test.
- 430 Functional annotation and enrichment
- 431 GO enrichment and KEGG enrichment of DEGs were performed using Fisher exact
- 432 test with Benjamini-Hochberg multiple testing adjustment. The results were
- visualized using R package. Gene set variation analysis (GSVA) ³¹ was performed
- using 50 hallmark-related gene sets, as described in the GSVA package.
- 435 Identification of hub regulons with SENIC
- 436 In order to investigate the gene regulatory network of different sample groups, we
- 437 utilized SCENIC ³² using the R.
- 438 Cell-cell communication analysis based on ligand-receptor pairs
- 439 Cell-cell communication at the molecular level was analyzed with CellPhoneDB ³³.
- 440 Cell trajectory analysis with Monocle
- 441 In order to reveal the development of malignant cells, we employed Monocle 2, an R
- package designed for single cell trajectories ³⁴. After obtaining the differentially
- 443 expressed genes through differential Gene Test function, the trajectories were
- visualized as 2D tSNE plots.
- 445 **Drug-target analysis with TCMID database**
- After obtaining the differentially expressed genes, we obtain the targeted relationship
- 447 between drugs and genes from the TCMID database
- 448 (http://www.megabionet.org/tcmid).
- 449 CNV Estimation
- 450 CopyKAT ³⁵ (Copynumber Karyotyping of Tumors), a R package was performed to
- separate tumor cells from normal cells using high-throughput sc-RNAseq data. Cells
- 452 with extensive genome-wide copy number aberrations (aneuploidy) are considered as
- 453 tumor cells, whereas stromal normal cells and immune cells often have 2N diploid or
- 454 near-diploid copy number profiles.
- 455 Statistical analysis
- 456 Box plots were drawn with the R base package. Hence, the boxes span from the 25th
- 457 to the 75th percentiles. Violin plots were generated by the ggplot2 R package.
- 458 Unpaired two-tailed t-tests was used to compare the difference between two groups.
- 459 While One-way analysis of variance (ANOVA) was used for multiple group
- 460 comparisons.
- 461 Data availability

462 The cancer genome atlas (TCGA) thyroid cancer (THCA) cohort were downloaded 463 from UCSC XENA (http://xena.ucsc.edu/). 464 465 References 466 1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and 467 mortality worldwide for 36 cancers in 185 countries. (2021). 468 469 2. Fagin JA, Wells SA, Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J 470 Med 375, 1054-1067 (2016). 471 472 3. Yu J, et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on 473 transfer learning radiomics. Nat Commun 11, 4807 (2020). 474 475 4. Cohen EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced 476 thyroid cancer: results from a phase II study. J Clin Oncol 26, 4708-4713 (2008). 477 478 5. Jiao C, et al. REGgamma ablation impedes dedifferentiation of anaplastic thyroid 479 carcinoma and accentuates radio-therapeutic response by regulating the 480 Smad7-TGF-beta pathway. Cell Death Differ 27, 497-508 (2020). 481 482 6. Laetitia G, Sven S, Fabrice J. Combinatorial Therapies in Thyroid Cancer: An 483 Overview of Preclinical and Clinical Progresses. Cells 9, (2020). 484 485 7. Hong CM, Ahn BC. Redifferentiation of Radioiodine Refractory Differentiated Thyroid



508 509 14. Oczko-Wojciechowska M, et al. Impact of the Tumor Microenvironment on the Gene 510 Expression Profile in Papillary Thyroid Cancer. Pathobiology 87, 143-154 (2020). 511 512 15. Jolly LA, et al. Fibroblast-Mediated Collagen Remodeling Within the Tumor 513 Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E 514 and Pten Loss. Cancer Res 76, 1804-1813 (2016). 515 516 16. Robertson A, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. 517 **78**, 533-537 (2020). 518 519 17. Mer A, et al. Biological and therapeutic implications of a unique subtype of NPM1 520 mutated AML. 12, 1054 (2021). 521 522 Job S, et al. Identification of Four Immune Subtypes Characterized by Distinct 18. 523 Composition and Functions of Tumor Microenvironment in Intrahepatic 524 Cholangiocarcinoma. 72, 965-981 (2020). 525 526 19. Wright G, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse 527 Large B Cell Lymphoma with Therapeutic Implications. 37, 551-568.e514 (2020). 528 529 20. Guruprasad P, Lee Y, Kim K, Ruella MJTJoem. The current landscape of single-cell

| 530 | | transcriptomics for cancer immunotherapy. 218, (2021). |
|-----|-----|---|
| 531 | | |
| 532 | 21. | Lin W, et al. Single-cell transcriptome analysis of tumor and stromal compartments of |
| 533 | | pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome |
| 534 | | Med 12, 80 (2020). |
| 535 | | |
| 536 | 22. | Stoeckius M, et al. Simultaneous epitope and transcriptome measurement in single |
| 537 | | cells. 14 , 865-868 (2017). |
| 538 | | |
| 539 | 23. | Butler A, Hoffman P, Smibert P, Papalexi E, Satija RJNb. Integrating single-cell |
| 540 | | transcriptomic data across different conditions, technologies, and species. 36, |
| 541 | | 411-420 (2018). |
| 542 | | |
| 543 | 24. | Jerby-Arnon L, et al. A Cancer Cell Program Promotes T Cell Exclusion and |
| 544 | | Resistance to Checkpoint Blockade. 175, 984-997.e924 (2018). |
| 545 | | |
| 546 | 25. | Peng J, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and |
| 547 | | malignant progression in pancreatic ductal adenocarcinoma. 29, 725-738 (2019). |
| 548 | | |
| 549 | 26. | Zhang X, et al. CellMarker: a manually curated resource of cell markers in human and |
| 550 | | mouse. 47 , D721-D728 (2019). |
| 551 | | |

| 552 | 27. | Zilionis R, et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers |
|---|-----|--|
| 553 | | Reveals Conserved Myeloid Populations across Individuals and Species. 50, |
| 554 | | 1317-1334.e1310 (2019). |
| 555 | | |
| 556 | 28. | Luoma A, et al. Molecular Pathways of Colon Inflammation Induced by Cancer |
| 557 | | Immunotherapy. 182 , 655-671.e622 (2020). |
| 558 | | |
| 559 | 29. | Habib N, et al. Disease-associated astrocytes in Alzheimer's disease and aging. Nat |
| 560 | | Neurosci 23, 701-706 (2020). |
| 561 | | |
| 562 | 30. | Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling Cell Type Abundance and |
| 563 | | Expression in Bulk Tissues with CIBERSORTx. Methods Mol Biol 2117, 135-157 |
| | | |
| 564 | | (2020). |
| 564 565 | | (2020). |
| | 31. | (2020). Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for |
| 565 | 31. | |
| 565 566 | 31. | Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for |
| 565 566 567 | 31. | Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for |
| 565 566 567 568 | | Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for microarray and RNA-seq data. 14 , 7 (2013). |
| 565566567568569 | | Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for microarray and RNA-seq data. 14 , 7 (2013). Aibar S, <i>et al.</i> SCENIC: single-cell regulatory network inference and clustering. 14 , |
| 565566567568569570 | | Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for microarray and RNA-seq data. 14 , 7 (2013). Aibar S, <i>et al.</i> SCENIC: single-cell regulatory network inference and clustering. 14 , |

| 574 | | ligand-receptor complexes. 15 , 1484-1506 (2020). |
|-----|-----|---|
| 575 | | |
| 576 | 34. | Trapnell C, et al. The dynamics and regulators of cell fate decisions are revealed by |
| 577 | | pseudotemporal ordering of single cells. Nat Biotechnol 32, 381-386 (2014). |
| 578 | | |
| 579 | 35. | Gao R, et al. Delineating copy number and clonal substructure in human tumors from |
| 580 | | single-cell transcriptomes. <i>Nat Biotechnol</i> , (2021). |
| 581 | | |
| 582 | 36. | Wolford C, et al. Transcription factor ATF3 links host adaptive response to breast |
| 583 | | cancer metastasis. 123 , 2893-2906 (2013). |
| 584 | | |
| 585 | 37. | Pere H, et al. A CCR4 antagonist combined with vaccines induces antigen-specific |
| 586 | | CD8+ T cells and tumor immunity against self antigens. 118, 4853-4862 (2011). |
| 587 | | |
| 588 | 38. | Berlato C, et al. A CCR4 antagonist reverses the tumor-promoting microenvironment |
| 589 | | of renal cancer. 127 , 801-813 (2017). |
| 590 | | |
| 591 | 39. | Vinci M, et al. Functional diversity and cooperativity between subclonal populations of |
| 592 | | pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nat Med 24, |
| 593 | | 1204-1215 (2018). |
| 594 | | |
| 595 | 40. | Rubio-Perez C, et al. Immune cell profiling of the cerebrospinal fluid enables the |

| 596 | | characterization of the brain metastasis microenvironment. 12, 1503 (2021). |
|-----|-----|--|
| 597 | | |
| 598 | 41. | Chen YP, et al. Single-cell transcriptomics reveals regulators underlying immune cell |
| 599 | | diversity and immune subtypes associated with prognosis in nasopharyngeal |
| 600 | | carcinoma. <i>Cell Res</i> 30 , 1024-1042 (2020). |
| 601 | | |
| 602 | 42. | Cook PJ, et al. Cox-2-derived PGE2 induces Id1-dependent radiation resistance and |
| 603 | | self-renewal in experimental glioblastoma. <i>Neuro Oncol</i> 18 , 1379-1389 (2016). |
| 604 | | |
| 605 | 43. | Jin S, Borkhuu O, Bao W, Yang YT. Signaling Pathways in Thyroid Cancer and Their |
| 606 | | Therapeutic Implications. <i>J Clin Med Res</i> 8 , 284-296 (2016). |
| 607 | | |
| 608 | 44. | Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1 |
| 609 | | is required for efficient apoptosis in tumor cells. <i>Cell Death Differ</i> 14 , 436-446 (2007). |
| 610 | | |
| 611 | 45. | Jung SN, et al. EGR1/GADD45alpha Activation by ROS of Non-Thermal Plasma |
| 612 | | Mediates Cell Death in Thyroid Carcinoma. <i>Cancers (Basel)</i> 13 , (2021). |
| 613 | | |
| 614 | 46. | Crawford NT, McIntyre AJ, McCormick A, D'Costa ZC, Buckley NE, Mullan PB. TBX2 |
| 615 | | interacts with heterochromatin protein 1 to recruit a novel repression complex to |
| 616 | | EGR1-targeted promoters to drive the proliferation of breast cancer cells. <i>Oncogene</i> |
| 617 | | 38 , 5971-5986 (2019). |

618 619 47. Ryu JW, et al. Paradoxical induction of growth arrest and apoptosis by EGF via the 620 up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells. 621 Oncotarget 8, 4181-4195 (2017). 622 623 48. Peng WX, et al. Egr-1 regulates irradiation-induced autophagy through Atg4B to 624 promote radioresistance in hepatocellular carcinoma cells. Oncogenesis 6, e292 625 (2017).626 627 49. Gonzalez-Navajas JM, et al. The Impact of Tregs on the Anticancer Immunity and the 628 Efficacy of Immune Checkpoint Inhibitor Therapies. Front Immunol 12, 625783 (2021). 629 630 50. Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid 631 cancer. Expert Rev Anticancer Ther 18, 149-159 (2018). 632 633 51. Lv M, et al. Manganese is critical for antitumor immune responses via cGAS-STING 634 and improves the efficacy of clinical immunotherapy. Cell Res 30, 966-979 (2020). 635 636 52. Marigo I, et al. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor 637 Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. 638 Cancer Cell 30, 377-390 (2016). 639

| 640 | 53. | Cortez MA, et al. Bone morphogenetic protein 7 promotes resistance to |
|-----|-----|---|
| 641 | | immunotherapy. Nat Commun 11, 4840 (2020). |
| 642 | | |
| 643 | 54. | Huang Z, et al. IL-27 promotes the expansion of self-renewing CD8(+) T cells in |
| 644 | | persistent viral infection. <i>J Exp Med</i> 216 , 1791-1808 (2019). |
| 645 | | |
| 646 | 55. | Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1 |
| 647 | | Therapy in Solid Tumors. Front Cell Dev Biol 8, 672 (2020). |
| 648 | | |
| 649 | 56. | Severson JJ, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of |
| 650 | | Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid |
| 651 | | Cancer. Cancer Immunol Res 3, 620-630 (2015). |
| 652 | | |
| 653 | 57. | Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by |
| 654 | | single-cell RNA-seq. 352 , 189-196 (2016). |
| 655 | | |
| 656 | 58. | Liu Y, Cao X. Characteristics and Significance of the Pre-metastatic Niche. Cancer |
| 657 | | <i>Cell</i> 30 , 668-681 (2016). |
| 658 | | |
| 659 | | |

Acknowledgments

This work was supported by Shanghai Municipal Commission of Health and Family Planning Commission (2019SY062).

Authors' contributions

BH J, ZS W, ZQ Y, and Y R conceived and designed the study. WL J, CG T, and ZS W contributed to carry out the experiments. BH J, CG H, and C Y contributed to data analysis. ZS W, BH J, and ZQ Y wrote the manuscript. YR, WL J, and ZQ Y revised the paper. All authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

671 Figure legends 672 Fig.1 Overall design and single cell atlas in papillary thyroid carcinoma. a 673 Workflow diagram showing the processing of samples. **b** UMAP plots of total cells, 674 colored by the sample origin (tumor, metastatic LN, and paracancerous tissues). c 675 Expression of cell marker genes. d Changes in frequency of multiple cell types and 676 clusters in tumors and metastatic LNs. Asterisks on the left of the vertical line denote 677 statistically significant differences between tumors and paracancerous tissues while 678 asterisks on the right are used to show statistically significant differences between 679 metastatic LNs and tumors. *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed t-tests. e 680 Interaction network constructed by CellPhoneDB. Size of circles and color of arrows 681 represent interaction counts, and brighter color and larger size mean more interaction 682 with other cell types. 683 Fig.2 Identification of malignant cells in epithelial cells. a Clonal substructure of 684 epithelial cells delineated by clustering single-cell copy number profiles inferred from 685 scRNA-seq data by CopyKAT. b UMAP plots of total epithelial cells, colored by the 686 sample origin (left and middle). Cell counts of malignant and non-malignant cells, 687 colored by the sample origin (right). c Differentiation trajectory of epithelial cells, 688 with each color coded for pseudotime (right) and clusters (left). d Heatmap of the area 689 under the curve (AUC) scores of transcription factor (TF) motifs estimated by 690 SCENIC. Shown are differentially activated motifs in malignant and non-malignant 691 cells, respectively. e High level of CREM and ETS1 predicted good prognosis in the 692 TCGA THCA cohort. Log-rank p value < 0.05 was considered as statistically 693 significant. f BHLHE40 was highly expressed in LN samples (p < 0.001). g GO 694 enrichment analysis of up-regulated genes in malignant lymphatic metastasis cells. 695 Fig.3 Heterogeneity of T cell populations. a UMAP plot of T cells color-coded by 696 their associated cell types. **b** Dotplot of cell markers; sizes of dots represent 697 abundance while color represents expression level. c Potential new cell markers. d 698 The protein level of EGR1 was decreased in tumor tissues compared with normal 699 tissues. e High level of EGR1 predicted good prognosis in the TCGA THCA cohort. 700 f Changes in frequency of multiple cell types in T cell populations. Asterisks on the 701 left of the vertical line denote statistically significant differences between tumors and 702 paracancerous tissues while asterisks on the right are used to show statistically 703 significant differences between LNs and tumors. *p < 0.05, **p < 0.01, ***p < 0.001, 704 two-tailed t-tests. g Violin of cell abundance predicted from the TCGA THCA cohort

705 by CIBERSORTx.

706

715

729

731

Fig.4 Novel cell type, named Protective EGR1⁺CD4⁺ T cells, and potential

707 therapeutic targets. a Differences in 50 hallmark pathway activities scored with

708 GSVA software. Shown are t values calculated by a linear model. **b** Heatmap of the

709 AUC scores of TF motifs estimated by SCENIC. Shown are differentially activated

710 motifs in CD4⁺ Tregs and Protective EGR1⁺CD4⁺T cells, respectively. **c-d** Heatmap

711 of positive and negative immune checkpoint expression on T cells in LNs (c) and

712 tumors (**d**), respectively.

713 Fig.5 Heterogeneity of Myeloid cell populations. a UMAP plot of Myeloid cells

714 color-coded by their associated cell types. **b** Dotplot of cell markers; sizes of dots

represent abundance while color represents expression level. c Changes in frequency

of multiple cell types and clusters in Myeloid cell populations. Asterisks on the left of

717 the vertical line denote statistically significant differences between tumors and

718 paracancerous tissues while asterisks on the right are used to show statistically

significant differences between LNs and tumors. *p < 0.05, **p < 0.01, ***p < 0.001,

720 two-tailed t-tests. d Violin of Macrophage abundance predicted from the TCGA

721 THCA cohort by CIBERSORTx. e Kaplan-Meier curves of DFS based on the

722 percentage of dendritic cells in the TCGA database.

723 Fig. 6 M2 macrophages were strongly enriched in the tumor tissues. a-b Heatmap

shows the differences in pathway activities scored by GSVA between different sample

725 origins. Shown are t values calculated by a linear model. c Heatmap of the AUC

scores of TF motifs estimated by SCENIC. Shown are differentially activated motifs

727 in subtypes of Myeloid cells, respectively. **d** Violin plot shows the expression level of

related genes in Macrophage subclusters (left) and cytokines in dendritic cells (right).

Supplementary information

730 Supplementary Fig. 1 Identification of major cell types in PTC. UMAP plots for

expression of the marker genes from **Fig 1c** and of additional marker genes for major

732 cell types. For B cells: CD19, MS4A1(CD20), CD38, CD79A, and CD79B; for CD4⁺

733 T cells: CD4 and CD3D; for CD8⁺T cells: CD8A and CD3D; for Endothelial cells:

734 CD34 and CD31(PECAM); for Epithelial cells: EPCAM and KRT18; for Fibroblasts:

735 COL1A1; for Myeloid cells: CD14, CD86, ITGAX, CD80, CD83, and ITGAM; for

736 Naive T cells: CCR7 and CD3D; for NKT cells: NKG7 and CD3D; for Plasma cells:

737 CD79A and SDC1. 738 Supplementary Fig. 2 Overview of the 28,205 single cells from tumors, 739 paracancerous tissues, and metastatic LNs. a The fraction of multiple cell types 740 originating from 7 tumor tissues, 6 paracancerous tissues, and 2 metastatic LNs. **b** The 741 fraction of multiple cell types originating from 15 samples. c The number of multiple 742 cell types. **d** Box plots of the number of transcripts. 743 Supplementary Fig. 3 Potential new cell markers in T cells. 744 Supplementary Fig. 4 DEGs related to CD4⁺Tregs and transitional EGR1⁺CD4⁺T 745 cells. a The expression of the maker genes in the TCGA THCA cohort. b Differences 746 in 50 hallmark pathway activities scored with GSVA software. Shown are t values 747 calculated by a linear model. c DEGs related to Protective EGR1⁺CD4⁺T cells in 748 tumors and LNs, respectively. **d** DEGs related to CD4⁺Tregs in tumors and LNs, 749 respectively. Upregulated genes and downregulated genes were colored in red and 750 blue, respectively. FC≥2. 751 Supplementary Fig. 5 External verification based on the TCGA data. a High level

of Macrophage abundance predicted poor prognosis in the TCGA THCA cohort, and

neutrophil was the opposite. **b** Kaplan-Meier survival curve for IFITM2.

752

